Call for comparative effectiveness research: Lowering A1c with sitagliptin, saxagliptin, or cinnamon

Journal of Managed Care Pharmacy

Volumn 15, Issue 8, 2009, Pages 696-700

  Fairman, Kathleen A ^a   Curtiss, Frederic R ^b  

^a Kathleen Fairman LTD   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; ANTIDIABETIC AGENT; CINNAMON EXTRACT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIMEPIRIDE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETIC DIET; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; KINESIOTHERAPY; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMARKETING SURVEILLANCE; SIDE EFFECT; SKIN MANIFESTATION; STROKE; TREATMENT OUTCOME;

EID: 70449657525     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2009.15.8.696     Document Type: Editorial

References (39)

1. Davis TM. Contemporary management of type 2 diabetes: blood glucose-lowering therapies and glycaemic targets. Med J Aust. 2008;189(5):246-248
2. Cefalu WT, Watson K. Intensive glycemic control and cardiovascular disease observations from the ACCORD study: now what can a clinician possibly think? Diabetes. 2008;57(5):1163-1165
3. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-71. Available at: http://content.nejm.org/cgi/content/full/ 356/24/2457. Accessed September 22, 2009. (Pubitemid 46919772)
4. U.S. Food and Drug Administration. Label and approval history for Avandia. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ index.cfm?fuseaction=Search.Label-ApprovalHistory#apphist. Accessed September 22, 2009.
5. U.S. Food and Drug Administration. Label and approval history for Actos. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm? fuseaction=Search.Label-ApprovalHistory#apphist. Accessed September 22, 2009.
6. Fairman KA, Curtiss FR. Still looking for health outcomes in all the wrong places? Misinterpreted observational evidence, medication adherence promotion, and value-based insurance design. J Manag Care Pharm. 2009;15(6):501-507 Available at: http://www.amcp.org/data/jmcp/501-507.pdf.
7. Hughes S. FDA advisory committee recommends cardiovascular safety studies for diabetes drugs. Heartwire. July 3, 2008. Available at: http://www.theheart. org/article/879839.do. Accessed September 22, 2009.
8. Landers SJ. FDA wants closer scrutiny of new diabetes drugs. Amednews.com. January 12, 2009. Available at: http://www.ama-assn.org/amed-news/ 2009/01/12/hlsa0112.htm. Accessed September 22, 2009.
9. Zarich SW, Nesto RW. What have we lost in the wake of the rosiglitzaone controversy? Endocr Pract. 2009;15(3):273-274
10. Pogach LM. Doctor, how certain are we that this diabetes medication is best for me? Ann Int Med. 2007;147(6):428-430
11. Traynor K. Diabetes specialists keep ACCORD data in perspective. AJHP News. March 15, 2008. Available at: http://www.ashp.org/import/News/ HealthSystemPharmacyNews/newsarticle.aspx?id=2767. Accessed September 12, 2009.
12. Fanning EL, Weissman PN, Menditto LA. Clinical practice effect of rosiglitazone discontinuation on glycemic control. Endocr Pract. 2009;15(3):270-272
13. Starner CI, Schafer JA, Heaton AH, Gleason PP. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events. J Manag Care Pharm. 2008;14(6):523-531 Available at: http://www.amcp.org/data/jmcp/JMCPMaga-523-531.pdf.
14. Drugs.com. Takeda receives new information on alogliptin (SYR-322). March 6, 2009. Available at: http://www.drugs.com/nda/syr-322-090306.html. Accessed September 22, 2009.
15. Matsuyama K. Takeda's diabetes drug alogliptin rejected by FDA (Update1). Bloomberg.com. June 27, 2009. Available at: http://www.bloomberg.com/apps/news? pid=20601124&sid=aphMYQhqhmNI. Accessed September 22, 2009.
16. Drugs.com. Complete response letter for alogliptin. June 28, 2009. Available at: http://www.drugs.com/nda/syr-322-090628.html. Accessed September 22, 2009.
17. Drugs.com. Cardiovascular outcomes trial for alogliptin. August 28, 2009. Available at: http://www.drugs.com/nda/syr-322-090828.html. Accessed September 22, 2009.
18. Onglyza (saxagliptin) product label. Available at: http://packageinserts. bms.com/pi/pi-onglyza.pdf. Accessed September 22, 2009.
19. Riley K. FDA News Release: FDA approves new drug treatment for type 2 diabetes. U.S. Food and Drug Administration. July 31, 2009. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm174780.htm. September 22, 2009.
20. Rosebraugh CJ. NDA Approval letter: NDA 22-350. U.S. Food and Drug Administration. July 31, 2008. Available at: http://www.accessdata.fda.gov/ drugsatfda-docs/appletter/2009/022350s000ltr.pdf. Accessed September 22, 2009.
21. McGuire S. Takeda submits NDA for Actos replacement as DPP-IV pipeline heats up. Medical Marketing & Media. January 7, 2008. Available at: http://www.mmm-online.com/takeda-submits-nda-for-actos-replacement-as-dpp-iv- pipeline-heats-up/article/100463/. Accessed September 22, 2009.
22. Crawford P. Effectiveness of cinnamon for lowering hemoglobin A1C in patients with type 2 diabetes: a randomized, controlled trial. J Am Board Fam Med. 2009;22(5):507-12. Available at: http://www.jabfm.org/cgi/reprint/22/5/507. Accessed September 22, 2009.
23. Blevins SM, Leyva MJ, Brown J, Wright J, Scofield RH, Aston CE. Effect of cinnamon on glucose and lipid levels in non-insulin-dependent type 2 diabetes. Diabetes Care. 2007;30(9):2236-37. Available at: http://care.diabetesjournals. org/content/30/9/2236.full.pdf+html. Accessed September 22, 2009. (Pubitemid 47359022)
24. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H; Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006;49(11):2564-2571
25. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE; Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29(12):2632-37. Available at: http://care.diabetesjournals. org/content/29/12/2632.full.pdf+html. Accessed September 22, 2009.
26. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29(12):2638-43. Available at: http://care.diabetesjournals.org/content/29/12/2638.full.pdf+html. Accessed September 22, 2009.
27. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28(10):1556-1568
28. Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled of glimepiride alone or on glimeperide and metformin. Diabetes Obes Metab. 2007;9(5):733-745 (Pubitemid 47261855)
29. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE; Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30(8):1979-87. Available at: http://care.diabetesjournals.org/content/30/8/1979.long. Accessed September 22, 2009.
30. Januvia (sitagliptin) product label. Available at: http://www.merck.com/ product/usa/pi-circulars/j/januvia/januvia-pi.pdf. Accessed September 22, 2009.
31. Curtiss FR, Fairman KA. Diabetes drug therapy - first do no harm. J Manag Care Pharm. 2008;14(7):658-660 Available at: http://www.amcp.org/data/jmcp/658- 660-CurtissFairman-Final.pdf.
32. U.S. Food and Drug Administration. Information for healthcare professionals - acute pancreatitis and sitagliptin (marketed as Januvia and Janumet). September 25, 2009. Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm183764.htm. Accessed September 28, 2009.
33. Dugoua JJ, Seely D, Perri D, et al. From type 2 diabetes to antioxidant activity: a systematic review of the safety and efficacy of common and cassia cinnamon bark. Can J Physiol Pharmacol 2007;85(9):837-847 (Pubitemid 350189725)
34. Drugstore.com. Price for 90 tablets of 100 mg Januvia. Available at: http://www.drugstore.com/pharmacy/prices/drugprice.asp?ndc=00006027731&trx= 1Z5006. Accessed September 16, 2009.
35. Drugstore.com. Price for 90 tablets of 2.5 mg Onglyza. Available at: http://www.drugstore.com/pharmacy/prices/drugprice.asp?ndc=00003421411&trx= 1Z5006. Accessed September 16, 2009.
36. Drugstore.com. Price for 90 tablets of 5.0mg Onglyza. Available at: http://www.drugstore.com/pharmacy/prices/drugprice.asp?ndc=00003421521&trx= 1Z5006. Accessed September 21, 2009.
37. Drugstore.com. Price for 180 tablets of 500 mg cinnamon. Available at: http://www.drugstore.com/search/search-results.asp?N=0&Ntx= mode%2Bmatchallpartial&Ntk=All&srchtree=5&Ntt=cinnamon+capsules& Go.x=13&Go.y=11. Accessed September 22, 2009.
38. Nathan DM. Finding new treatments for diabetes - how many, how fast...how good? N Engl J Med. 2008;356(5):437-440
39. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Int Med. 2007;147(6):386-99. Available at: http://www.annals.org/cgi/reprint/ 147/6/386.pdf?ijkey=c2a022fc930eced2876a2a1297cf9a27d1765523. Accessed September 16, 2009. (Pubitemid 351664540)